Cellectis S.A. Files Form 6-K for March 2025
Ticker: CLLS · Form: 6-K · Filed: Mar 7, 2025 · CIK: 1627281
Sentiment: neutral
Topics: regulatory-filing, sec-filing, form-6k
TL;DR
Cellectis filed a 6-K for March 2025, incorporating press release into F-3/S-8 filings.
AI Summary
Cellectis S.A. filed a Form 6-K on March 7, 2025, to report information for the month of March 2025. This filing includes a press release (Exhibit 99.1) which is incorporated by reference into the company's existing registration statements on Form F-3 and Form S-8. The company is a biological products developer, not involved in diagnostic substances.
Why It Matters
This filing serves as an update for investors and regulatory bodies, incorporating previous disclosures into ongoing registration statements.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previously issued information into existing registration statements, with no new material financial or operational disclosures.
Key Players & Entities
- Cellectis S.A. (company) — Registrant
- 001-36891 (company) — Commission File Number
- 333-265826 (company) — Form F-3 Registration Statement Number
- 333-204205 (company) — Form S-8 Registration Statement Number
- 333-214884 (company) — Form S-8 Registration Statement Number
- 333-222482 (company) — Form S-8 Registration Statement Number
- 333-227717 (company) — Form S-8 Registration Statement Number
- 333-258514 (company) — Form S-8 Registration Statement Number
- 333-267760 (company) — Form S-8 Registration Statement Number
- 333-273777 (company) — Form S-8 Registration Statement Number
FAQ
What type of company is Cellectis S.A.?
Cellectis S.A. is a company in the biological products sector, specifically not involved with diagnostic substances.
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer filed for the month of March 2025, including a press release as Exhibit 99.1.
Which registration statements does this filing incorporate information into?
This filing is incorporated by reference into Cellectis S.A.'s registration statements on Form F-3 (No. 333-265826) and Form S-8 (multiple numbers listed).
What is the principal executive office address of Cellectis S.A.?
The principal executive office is located at 8, rue de la Croix Jarry, 75013 Paris, France.
Does Cellectis S.A. file annual reports under Form 20-F or 40-F?
Cellectis S.A. files annual reports under cover of Form 20-F, as indicated by the checkmark in the filing.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 7, 2025 regarding Cellectis S.A. (CLLS).